Rein Therapeutics Inc (RNTX) - Net earnings per share (EPS TTM)

Symbol and logo of brand aileronrx.com (RNTX)

The rare disease sector is characterized by a lack of current operating revenue due to prolonged clinical stages. Rein Therapeutics Inc relies on a unique cell protection ecosystem that creates exclusive therapy protocols. Cost optimization is achieved by outsourcing production to third-party contractors. This 12-month net income per share chart reflects the development trend, where the value is maintained at -1.57.

RNTX (aileronrx.com) Earnings per share for the last 12 months history from 07/04/2022 to 11/18/2026

Comprehensive metric breakdowns and analytics for Rein Therapeutics, Inc. (RNTX)

General company analysis:aileronrx.com (RNTX)
Mass-produced product of Rein Therapeutics Inc.

Investors are evaluating Rein Therapeutics Inc (RNTX) through the lens of orphan drug development efficiency. This metric calculates annual net income per share, excluding the impact of total issuance volume. An analysis of the TTM net income per share allows for the identification of abnormal revenue spikes and overpayment risks. Amid asset reorganization, this indicator reflects the real value of the business. Long-term consensus depends on the successful clinical progression of the portfolio.

Competitors of Rein Therapeutics Inc (RNTX)

VRTX: Net earnings per share for the last 12 months|Earnings per one share for the last 12 months ALNY|INSM: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months United Therapeutics Corp. (UTHR)|BMRN (BioMarin) - Net earnings per share (EPS TTM)|Earnings per share for the last 12 months BBIO (BridgeBio)|Earnings per share for the last twelve months bgm.ltd (BGM)|COGT (Cogent Biosciences Inc) - Earnings per share for the trailing year|Earnings per share for the last twelve months Xeris Biopharma Holdings XERS|KROS (Keros Pharma) - Earnings per one share for the last 12 months|Arcturus Therapeutics - Net earnings per share (EPS TTM)|Earnings per share for the trailing year ETON (Eton Pharmaceuticals)|KMDA: Net earnings per share (EPS TTM)|Fulcrum Therapeutics Inc (FULC) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months abeonatherapeutics.com|MREO: Earnings per share for the trailing year|Net earnings per share (EPS TTM) PLX|Net earnings per share for the last 12 months Pliant Therapeutics, Inc. PLRX|Net earnings per share (EPS TTM) APLT (Applied Therapeutics Inc.)|Net earnings per share (EPS TTM) Gelteq Limited Inc GELS|Aytu BioPharma, Inc. - Net earnings per share (EPS TTM)|chemomab.com (CMMB) - Net earnings per share for the last 12 months|SRx Health (SRXH) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Polyrizon Ltd. (PLRZ)|Net earnings per share for the last 12 months AEZS|Net earnings per share for the last 12 months Cyclo Therapeutics Inc. (CYTH)|Net earnings per share for the last 12 months INZY (inozyme.com)|RPHM - Net earnings per one share for the last twelve months|Net earnings per share (EPS TTM) CSCI (cosciensbio.com)